Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | VHL | P40337 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805042 | 0.78 | — | — | |
| SCHEMBL933778 | 0.76 | — | — | |
| SCHEMBL15200484 | 0.76 | — | — | |
| SCHEMBL8868767 | 0.76 | — | — | |
| SCHEMBL1578634 | 0.76 | — | — | |
| SCHEMBL2093209 | 0.76 | — | — | |
| SCHEMBL19399866 | 0.76 | — | — | |
| SCHEMBL2093204 | 0.76 | — | — | |
| SCHEMBL22792608 | 0.76 | — | — | |
| SCHEMBL10475738 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113943281-B | Synthetic method and application of isoxazole pyrimidine derivative | 深圳湾实验室 | 2023-08-15 | — | — | CN | disclosed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
| US-6022868-A | TREATING DISEASES IN THE CENTRAL NERVOUS SYSTEM RELATED TO MALFUNCTIONING OF THE NICOTINIC CHOLINERGIC SYSTEM. | NOVO NORDISK ALS (DK) | 2000-02-08 | — | — | US | disclosed |
| EP-0842172-A1 | NOVEL SUBSTITUTED AZACYCLIC OR AZABICYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997001556-A1 | NOVEL SUBSTITUTED AZACYCLIC OR AZABICYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | MEN1 483/4885KMT2A 3004/4885VHL 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.